Keystone Symposia

Hotel Palace Berlin Floorplan

Registered Attendees

Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2018

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

21st-Century Drug Discovery and Development for Global Health (S3)

Organizer(s) Ken Duncan, Elizabeth Winzeler and Lluís Ballell
October 17—20, 2018
Hotel Palace Berlin • Berlin, Germany
Discounted Abstract Deadline: Jun 19, 2018
Abstract Deadline: Jul 17, 2018
Scholarship Deadline: Jun 19, 2018
Discounted Registration Deadline: Aug 16, 2018

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation

Summary of Meeting:
Infectious diseases cause substantial morbidity and mortality in the developing world. The medicines available today are often inconvenient to use or result in side effects, and many are being lost to emerging drug resistance. There remains an urgent need to discover and develop the next generation of transformative medicines that are more efficacious, more highly targeted, and have a better safety profile. This will only be achieved through the application of state-of-the-art drug discovery tools, technologies and approaches. This meeting will focus on diseases caused by parasitic organisms and bacteria, including malaria, neglected tropical diseases, diarrheal disease and tuberculosis. The goals of this meeting are to improve understanding of the disease burden and challenges faced in developing new therapies, to highlight examples of progress towards new drug candidates, and to foster communication and collaboration among communities of researchers working in global health across the spectrum from research to the clinic. The meeting will be of interest to basic scientists as well as drug discovery and development experts wanting to gain a better understanding of the challenges and opportunities in global health.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time

The meeting will begin on Wednesday, October 17 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Saturday, October 20 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Sunday, October 21 in order to fully experience the meeting.


Arrival and Registration

Foyer 2nd Floor
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Foyer 2nd Floor


New Therapeutics for Global Health

Bordeaux I-II
* Ken Duncan, Bill & Melinda Gates Foundation, USA

Nathalie Strub Wourgaft, Drugs for Neglected Diseases Initiative, DNDi, Switzerland
Transformative New Therapies for Human African trypanosomiasis

Thierry T. Diagana, Novartis Institute for Tropical Diseases, USA
Progress with the Clinical Development of Cipargamin (KAE609) and Ganaplacide (KAF156) for the Treatment of Malaria

Lluis Ballell, GlaxoSmithKline, Spain
Global Health GSK R&D in Tres Cantos – Introducing GSK701 and GSK286 as Novel Preclinical Candidates against Malaria and TB

Joseph D. Turner, Liverpool School of Tropical Medicine, UK
Short Talk: Novel Anti-Wolbachia Drugs as Short-Course Macrofilaricides for Onchocerciasis

Robust Target Validation - What Does it Mean?

Bordeaux I-II
* Anil Koul, Institute of Microbial Technology, India

Elizabeth A. Winzeler, University of California, San Diego, USA
Multidisciplinary Approaches to the Discovery of Chemoprotective Drugs and Targets for Malaria

Dirk Schnappinger, Weill Cornell Medical College, USA
Combining Chemical Probes and Genetic Knockdowns to Validate Drug Targets in Mycobacterium tuberculosis

Boris Striepen, University of Pennsylvania, USA
Using Molecular Genetics to Understand and Combat Cryptosporidium

Andrew Fraser, University of Toronto, Canada
Short Talk: Dissecting the Pathway for Rhodoquinone Biosynthesis in C. elegans: It all Starts at the Beginning

Transfer to Grand Challenges Event at Estrel Congress Center

Lunch with Grand Challenges

Estrel Congress Ctr, Convention Hall I-A/B
Joint Keynote Session and Panel Discussion with Grand Challenges: Innovation in Drug Discovery
Ken Duncan, The Bill & Melinda Gates Foundation, USA

Spotlight Talk
Kelly Chibale, University of Cape Town, South Africa

Panel Discussion: Combatting Antimicrobial Resistance through Drug Discovery and Innovation
*Sally Davies, UK Department of Health, UK
Stephen Baker, University of Oxford, UK
Renu Swarup, Department of Biotechnology, India

Closing Keynote
Lynda Stuart, The Bill & Melinda Gates Foundation, USA

Estrel Convention Hall II
Networking and Welcome Mixer with Grand Challenges and Keystone Symposia

Estrel Congress Ctr, Convention Hall I-A/B
Return Transfer to Hotel

Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Burgund I-III


Importance of Chemical Diversity in Seeking New Leads

Bordeaux I-II
* Courtney Cortez Aldrich, University of Minnesota, USA

Xiaopeng Bai, GlaxoSmithKline, USA
Experience with DNA-Encoded Libraries in Search for New Leads against TB

E. Paige Stout, Sirenas, USA
Sirenas Biochemometrics Platform: Transforming the Search for New Medicines

Coffee Break

Judy A. Sakanari, University of California, San Francisco, USA
Identifying Anti-Filarial Candidates using a Multifaceted Screening Funnel

Charles E. Mowbray, Drugs for Neglected Diseases Initiative, Switzerland
A New Era of Orally Active Treatments for Leishmaniasis Patients

Jennifer Elizabeth Collins, University of Central Florida, USA
Short Talk: Novel Antiplasmodial Compounds from Fungi

On Own for Lunch

Poster Setup

Burgund I-III
Poster Viewing

Burgund I-III
Coffee Available

Burgund I-III
Alternative Approaches to Drug Delivery - Opportunities and Challenges

Bordeaux I-II
* Anna Upton, TB Alliance, USA

Paul L. Feldman, Intarcia Therapeutics, USA
Application of the Intarcia Medici Drug Delivery SystemTM for Long-Acting HIV Prevention for Global Health

Andrew Martin Bellinger, Lyndra, USA
Development of Oral, Ultra Long-Lasting, Sustained Release Therapies in the Fight against Malaria and HIV

Arnab Chatterjee, Calibr at Scripps Research, USA
Chemoprophylaxis for Prevention of Malaria Infection

Daniel Greenwood, Francis Crick Institute, UK
Short Talk: Subcellular Antibiotic Visualisation Reveals a Dynamic Drug Reservoir in Mycobacterium tuberculosis-Infected Macrophages

Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Burgund I-III
Poster Session 1

Burgund I-III


Poster Setup

Burgund I-III
Poster Viewing

Burgund I-III
Improving Target and Phenotypic-Based Approaches

Bordeaux I-II
* Tanya Parish, Infectious Disease Research Institute, USA

Leann M. Tilley, University of Melbourne, Australia
The Proteasome as a Target for New Antimalarial Drugs

Kirsten Hanson, University of Texas at San Antonio, USA
Profiling Compounds against Liver Stage Malaria

Beatriz Baragana, University of Dundee, UK
Short Talk: Lysyl tRNA Synthetase as a Drug Target in Apicomplexan Parasites

Nyssa Drinkwater, Monash University, Australia
Short Talk: Rational Design of a Multi-Target Antimalarial Compound with in vivo Activity

Coffee Break

Deborah T. Hung, Broad Institute of MIT & Harvard, USA
Multiplex Screening of an M. tuberculosis Hypomorph Library Simultaneously Identifies Lead and Target

Marc Gitzinger, BioVersys AG, Switzerland
A SMARt Approach to Reversing Drug Resistance in TB and Deploying the Hidden Potential of Current TB Drugs

Bryan J. Berube, Infectious Disease Research Institute, USA
Short Talk: MenA Inhibitors Are Bactericidal against Mycobacterium tuberculosis Alone and in Combination with Electron-Transport Chain Inhibitors


Burgund I-III
Poster Session 2

Burgund I-III
Workshop: Opportunities for Repurposing to Discover New Candidates or Mature Starting Points

Bordeaux I-II
* Elnaz Menhaji-Klotz, Bill & Melinda Gates Medical Research Institute, USA

* Khisimuzi E. Mdluli, Bill & Melinda Gates Medical Research Institute, USA

Oluyomi S. Adeyemi, Landmark University, Nigeria
Drug Repurposing and Screening of Libraries of Chemical Compounds to Identify New Anti-Parasitic Agents

Samuel Arnold, University of Washington, USA
A Second Chance for Your Favorite Protozoan Target: Repositioning Opportunities for Treatment of Cryptosporidosis

Giancarlo Biagini, Liverpool School of Tropical Medicine, UK
Antimalarial Pharmacology of Primaquine: Attempting to Solve a 70-Year-Old Puzzle

Elena Fernandez Alvaro, GlaxoSmithKline, Spain
Repurposing Opportunities for the Treatment of MDR Bacterial Enteric Infections

Malkeet Kumar, University of Cape Town, South Africa
Repositioning the Antihistamine Drug Astemizole as an Anti-Plasmodial Agent

Rob Leurs, Vrije Universiteit Amsterdam, Netherlands
Parasite-Specific Cyclic Nucleotide Phosphodiesterase Inhibitors to Target Neglected Parasitic Diseases (PDE4NPD)

Rose C. Lopeman, Aston University, UK
Faropenem and Clavulanate Exhibit Additive Effect against Mycobacterium abscessus in vitro

Coffee Available

Burgund I-III
Translational Tools for Predicting Efficacy and Resistance

Bordeaux I-II
* Robert S. Wallis, Aurum Institute, South Africa

Wesley C. Van Voorhis, University of Washington, USA
Pharmacodynamic Modeling of Anti-Cryptosporidium Drug Efficacy

Yingda L. Xie, NIAID, National Institutes of Health, USA
Improving Phase 2a TB Drug Development Models through PET/CT Imaging (NexGen EBA)

Cristina Donini, Medicines for Malaria Venture, Switzerland
Role of Volunteer Infection Studies in Prioritizing the Next Generation of Clinical Candidates in Malaria

Thomas Spangenberg, Merck, Switzerland
Short Talk: Evaluation of the Pharmacokinetic-Pharmacodynamic Relationship of Praziquantel in the Schistosoma mansoni Mouse Model

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

Bordeaux I-II
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Burgund I-III
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Burgund I-III



*Session Chair †Invited, not yet responded.

We gratefully acknowledge support for this conference from:

Directors' Fund

These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

Bill & Melinda Gates Foundation

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

BioVersys AG

Intarcia Therapeutics, Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Corporate Relations, Email:,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Nick Dua, Senior Director, Communications, Email:,
Phone:+1 970-262-1179